Compare GHG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | RIGL |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 564.7M |
| IPO Year | 2017 | 2000 |
| Metric | GHG | RIGL |
|---|---|---|
| Price | $1.15 | $38.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 7.7K | ★ 339.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $19.02 | N/A |
| Revenue Next Year | $8.26 | $12.75 |
| P/E Ratio | ★ $5.76 | $88.00 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $1.11 | $18.24 |
| 52 Week High | $2.78 | $52.24 |
| Indicator | GHG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 74.26 |
| Support Level | $1.14 | $33.39 |
| Resistance Level | $1.16 | $44.85 |
| Average True Range (ATR) | 0.02 | 1.63 |
| MACD | 0.00 | 0.44 |
| Stochastic Oscillator | 80.00 | 81.09 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.